Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Via Analysis of Immunoinflammation-related Protein Complexes in Blood

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05410015

Enrollment

300

Registered

2022-06-08

Start date

2022-02-03

Completion date

2026-02-03

Last updated

2022-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

Detailed description

100 cases in normal ovarian control group, 100 cases in benign ovarian disease group and 100 cases in malignant ovarian epithelial carcinoma group will be studied. Change regularity of ovarian cancer specific immune inflammation-related protein complexes in blood will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.

Interventions

OTHERNormal clinical treatment without intervention

Normal clinical treatment without intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Female * Normal ovary control * Ovarian benign disease * Ovarian malignant epithelial carcinoma

Exclusion criteria

* Male * Age above 70 * Suffering from other malignant tumors * Non-compliant patient

Design outcomes

Primary

Measure	Time frame	Description
Immune Inflammation-Related Protein Pomplexes	2 years	The change of immune inflammation-related protein complexes

Countries

China

Contacts

Primary ContactPeng Peng, MD

pengp1999@163.com+86-13521361934

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026